RADIOTHERAPY GRANT

Article

AlphaMed Inc. announced that it received a $500,000 two-year STTR Phase II grant award from the National Cancer Institute to further develop a targeted radiotherapy for metastatic melanoma.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.